1: MacDowell KS, Sayd A, García-Bueno B, Caso JR, Madrigal JL, Leza JC. Effects 
of the antipsychotic paliperidone on stress-induced changes in the 
endocannabinoid system in rat prefrontal cortex. World J Biol Psychiatry. 2016 
Mar 18:1-14. [Epub ahead of print] PubMed PMID: 26987678.

2: Tsai MC, Chang PT, Yang CH, Liu ME. The Delirium Related to Oral Paliperidone 
in Dementia: A Case Report. J Clin Psychopharmacol. 2016 Apr;36(2):184-5. doi: 
10.1097/JCP.0000000000000472. PubMed PMID: 26872118.

3: Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre 
P. Comparison of Medicaid spending in schizoaffective patients treated with once 
monthly paliperidone palmitate or oral atypical antipsychotics. Curr Med Res 
Opin. 2016 Apr;32(4):759-769. Epub 2016 Feb 2. PubMed PMID: 26750639.

4: Yang CH, Juang KD, Chou PH, Chan CH. A Case Report of Probable Paliperidone 
ER-Induced Serotonin Syndrome in a 17-Year-Old Taiwanese Female With New Onset 
Psychosis. Medicine (Baltimore). 2016 Mar;95(9):e2930. doi: 
10.1097/MD.0000000000002930. PubMed PMID: 26945397.

5: Alphs L, Fu DJ, Turkoz I. Paliperidone for the Treatment of Schizoaffective 
Disorder. Expert Opin Pharmacother. 2016 Mar 2. [Epub ahead of print] PubMed 
PMID: 26934062.

6: Qiao Y, Yang F, Li C, Guo Q, Wen H, Zhu S, Ouyang Q, Shen W, Sheng J. Add-on 
effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by 
risperidone or paliperidone. Psychiatry Res. 2016 Mar 30;237:83-9. doi: 
10.1016/j.psychres.2015.12.033. Epub 2015 Dec 28. PubMed PMID: 26921057.

7: Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon 
P. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other 
Antipsychotics for the Maintenance Treatment of Schizophrenia in France. 
Pharmacoeconomics. 2016 Apr;34(4):363-91. doi: 10.1007/s40273-015-0348-x. PubMed 
PMID: 26883132.

8: Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L. Rapid onset of treatment effects 
on psychosis, depression, and mania in patients with acute exacerbation of 
schizoaffective disorder following treatment with oral extended-release 
paliperidone. J Affect Disord. 2016 Mar 15;193:381-90. doi: 
10.1016/j.jad.2015.12.060. Epub 2015 Dec 31. PubMed PMID: 26802315.

9: Kim MK, Kim B, Lee KS, Kim CM, Bang SY, Choi TK, Lee SH. White-matter 
connectivity related to paliperidone treatment response in patients with 
schizophrenia. J Psychopharmacol. 2016 Mar;30(3):294-302. doi: 
10.1177/0269881115625114. Epub 2016 Jan 11. PubMed PMID: 26755544.

10: Ravenstijn P, Remmerie B, Savitz A, Samtani MN, Nuamah I, Chang CT, De 
Meulder M, Hough D, Gopal S. Pharmacokinetics, safety, and tolerability of 
paliperidone palmitate 3-month formulation in patients with schizophrenia: A 
phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016 
Mar;56(3):330-9. doi: 10.1002/jcph.597. Epub 2015 Oct 5. PubMed PMID: 26189570.

11: Cordiner M, Shajahan P, McAvoy S, Bashir M, Taylor M. Effectiveness of 
long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month 
follow up and comparison between paliperidone palmitate, risperidone long-acting 
injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol. 2016 
Feb;6(1):22-32. doi: 10.1177/2045125315623168. PubMed PMID: 26913175; PubMed 
Central PMCID: PMC4749742.

12: Karslıoǧlu EH, Özalp E, Çayköylü A. Paliperidone Palmitate-induced Urinary 
Incontinence: A Case Report. Clin Psychopharmacol Neurosci. 2016 Feb 
29;14(1):96-100. doi: 10.9758/cpn.2016.14.1.96. PubMed PMID: 26792046; PubMed 
Central PMCID: PMC4730936.

13: Struye A, Depuydt C, Abdel Sater E, Dubois V. Toxic Epidermal Necrolysis 
Related to Paliperidone Palmitate: First Case Report. J Clin Psychopharmacol. 
2016 Feb 26. [Epub ahead of print] PubMed PMID: 26928057.

14: Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, Schotte A, Hough 
D, Fleischhacker WW. Efficacy and Safety of Paliperidone Palmitate 3-Month 
Formulation for Patients with Schizophrenia: A Randomized, Multicenter, 
Double-Blind, Noninferiority Study. Int J Neuropsychopharmacol. 2016 Feb 22. pii: 
pyw018. doi: 10.1093/ijnp/pyw018. [Epub ahead of print] PubMed PMID: 26902950.

15: Gomeni R, Bressolle F, Fava M. Response Surface Analysis and Non-Linear 
Optimization Algorithm For Maximization of Clinical Drug Performance: Application 
to Extended Release and Long-Acting-Injectable Paliperidone. J Clin Pharmacol. 
2016 Feb 22. doi: 10.1002/jcph.724. [Epub ahead of print] PubMed PMID: 26899406.

16: Alphs L, Mao L, Lynn Starr H, Benson C. A pragmatic analysis comparing 
once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in 
patients with schizophrenia. Schizophr Res. 2016 Feb;170(2-3):259-64. doi: 
10.1016/j.schres.2015.12.012. Epub 2015 Dec 29. PubMed PMID: 26742509.

17: Darville N, van Heerden M, Erkens T, De Jonghe S, Vynckier A, De Meulder M, 
Vermeulen A, Sterkens P, Annaert P, Van den Mooter G. Modeling the Time Course of 
the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate 
Nano-/Microcrystals and Polystyrene Microspheres in the Rat. Toxicol Pathol. 2016 
Feb;44(2):189-210. doi: 10.1177/0192623315618291. Epub 2015 Dec 23. PubMed PMID: 
26698322.

18: Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N. Genotype and 
co-medication dependent CYP2D6 metabolic activity: effects on serum 
concentrations of aripiprazole, haloperidol, risperidone, paliperidone and 
zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84. doi: 
10.1007/s00228-015-1965-1. Epub 2015 Oct 30. PubMed PMID: 26514968.

19: Chue P, Chue J. A critical appraisal of paliperidone long-acting injection in 
the treatment of schizoaffective disorder. Ther Clin Risk Manag. 2016 Jan 
27;12:109-16. doi: 10.2147/TCRM.S81581. eCollection 2016. Review. PubMed PMID: 
26869795; PubMed Central PMCID: PMC4737499.

20: Koshikawa Y, Takekita Y, Kato M, Sakai S, Onohara A, Sunada N, Nishida K, 
Yoshimura M, Fabbri C, Serretti A, Kinoshita T. The Comparative Effects of 
Risperidone Long-Acting Injection and Paliperidone Palmitate on Social 
Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot 
Trial. Neuropsychobiology. 2016;73(1):35-42. doi: 10.1159/000442209. Epub 2016 
Jan 27. PubMed PMID: 26812618.